Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jun;35(6):637–641. doi: 10.1111/j.1365-2125.1993.tb04194.x

Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment.

R M Barr 1, F Lawlor 1, M R Judge 1, P Courtney 1, R Barlow 1, A Kobza Black 1, A I Mallet 1, M W Greaves 1
PMCID: PMC1381608  PMID: 8329291

Abstract

1. Previous, in vitro, studies have established the synthesis of platelet activating factor (PAF) by the 're-modelling' pathways in which the activation of a phospholipase A2 (PLA2) enzyme catalyses the hydrolysis of an ether-acyl-phosphocholine to give concomitant release of lyso-PAF, the immediate precursor of PAF, and arachidonic acid, the precursor of the icosanoids. The aim of this study was to investigate the relationship between PAF and eicosanoid release in human skin, and to study the effect of treatment of skin with a topical steroid, on the release of PAF, lyso-PAF and arachidonic acid. 2. A novel assay procedure was developed for the simultaneous assay of PAF and lyso-PAF in skin exudates from abrasions and suction blisters in normal human skin. In addition we assayed arachidonic acid and prostaglandin E2 (PGE2), a representative eicosanoid. 3. The mean amounts of mediator recovered in the first 30 min period following abrasion were PAF 0.43, lyso-PAF 11.9, PGE2 25.7 and arachidonic acid 760 pmol/sample. The molar ratio of PAF:lyso-PAF:arachidonic acid in skin exudates from abrasions was 1:30:1800 and in suction blister exudates was 1:90:3660. 4. Time course studies showed a decline in the recoveries of arachidonic acid and lyso-PAF, of about 50% in 2 h. In contrast, PAF was recovered in exudates at a constant rate over 2 h but PGE2 release decreased by more than 90% after the initial 30 min period. 5. Topical application under occlusion, of 0.05% clobetasol propionate, a potent corticosteroid, significantly reduced lyso-PAF by 30% in suction blister exudates but did not significantly alter the concentrations of PAF or arachidonic acid.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alam I., Silver M. J. Acetyltransferase activity in human platelet microsomes and washed platelets. Biochim Biophys Acta. 1986 Oct 29;884(1):67–72. doi: 10.1016/0304-4165(86)90228-x. [DOI] [PubMed] [Google Scholar]
  2. Archer C. B., Page C. P., Morley J., MacDonald D. M. Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man. Br J Dermatol. 1985 Mar;112(3):285–290. doi: 10.1111/j.1365-2133.1985.tb04855.x. [DOI] [PubMed] [Google Scholar]
  3. Barr R. M., Koro O., Francis D. M., Black A. K., Numata T., Greaves M. W. The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions. Br J Pharmacol. 1988 Jul;94(3):773–780. doi: 10.1111/j.1476-5381.1988.tb11588.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Black A. K., Greaves M. W., Hensby C. N., Plummer N. A., Eady R. A. A new method for recovery of exudates from normal and inflamed human skin. Clin Exp Dermatol. 1977 Sep;2(3):209–216. doi: 10.1111/j.1365-2230.1977.tb02560.x. [DOI] [PubMed] [Google Scholar]
  5. Camussi G., Tetta C., Baglioni C. The role of platelet-activating factor in inflammation. Clin Immunol Immunopathol. 1990 Dec;57(3):331–338. doi: 10.1016/0090-1229(90)90108-3. [DOI] [PubMed] [Google Scholar]
  6. Camussi G., Tetta C., Bussolino F., Baglioni C. Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases. J Exp Med. 1988 Oct 1;168(4):1293–1306. doi: 10.1084/jem.168.4.1293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chilton F. H., Connell T. R. 1-ether-linked phosphoglycerides. Major endogenous sources of arachidonate in the human neutrophil. J Biol Chem. 1988 Apr 15;263(11):5260–5265. [PubMed] [Google Scholar]
  8. Clay K. L., Murphy R. C., Andres J. L., Lynch J., Henson P. M. Structure elucidation of platelet activating factor derived from human neutrophils. Biochem Biophys Res Commun. 1984 Jun 29;121(3):815–825. doi: 10.1016/0006-291x(84)90751-4. [DOI] [PubMed] [Google Scholar]
  9. Davidson F. F., Dennis E. A., Powell M., Glenney J. R., Jr Inhibition of phospholipase A2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids. J Biol Chem. 1987 Feb 5;262(4):1698–1705. [PubMed] [Google Scholar]
  10. Dell A., Tiller P. R. A novel mass spectrometric procedure to rapidly determine the position of O-acylated residues in the sequence of naturally occurring oligosaccharides. Biochem Biophys Res Commun. 1986 Mar 28;135(3):1126–1134. doi: 10.1016/0006-291x(86)91045-4. [DOI] [PubMed] [Google Scholar]
  11. FOLCH J., LEES M., SLOANE STANLEY G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed] [Google Scholar]
  12. Flower R. J. Background and discovery of lipocortins. Agents Actions. 1986 Jan;17(3-4):255–262. doi: 10.1007/BF01982616. [DOI] [PubMed] [Google Scholar]
  13. Kaluzny M. A., Duncan L. A., Merritt M. V., Epps D. E. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res. 1985 Jan;26(1):135–140. [PubMed] [Google Scholar]
  14. Kobza Black A., Greaves M. W., Hensby C. N. The effect of systemic prednisolone on arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous inflammation. Br J Clin Pharmacol. 1982 Sep;14(3):391–394. doi: 10.1111/j.1365-2125.1982.tb01996.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mallet A. I., Cunningham F. M. Structural identification of platelet activating factor in psoriatic scale. Biochem Biophys Res Commun. 1985 Jan 16;126(1):192–198. doi: 10.1016/0006-291x(85)90590-x. [DOI] [PubMed] [Google Scholar]
  16. Michel L., Denizot Y., Thomas Y., Jean-Louis F., Heslan M., Benveniste J., Dubertret L. Production of paf-acether by human epidermal cells. J Invest Dermatol. 1990 Nov;95(5):576–581. doi: 10.1111/1523-1747.ep12505563. [DOI] [PubMed] [Google Scholar]
  17. Oda M., Satouchi K., Yasunaga K., Saito K. Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. J Immunol. 1985 Feb;134(2):1090–1093. [PubMed] [Google Scholar]
  18. The Abortion Act twenty years on. Lancet. 1988 Jan 16;1(8577):91–92. [PubMed] [Google Scholar]
  19. Weintraub S. T., Lear C. S., Pinckard R. N. Analysis of platelet-activating factor by GC-MS after direct derivatization with pentafluorobenzoyl chloride and heptafluorobutyric anhydride. J Lipid Res. 1990 Apr;31(4):719–725. [PubMed] [Google Scholar]
  20. Wong E., Barr R. M., Cunningham F. M., Mistry K., Woollard P. M., Mallet A. I., Greaves M. W. Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis. Br J Clin Pharmacol. 1986 Dec;22(6):627–632. doi: 10.1111/j.1365-2125.1986.tb02949.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wykle R. L., Malone B., Snyder F. Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem. 1980 Nov 10;255(21):10256–10260. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES